HIF2A is activated in clear cell renal cell carcinoma (ccRCC) through mutations in the von Hippel-Lindau tumour suppressor gene (VHL), which under normal conditions targets HIF2A for proteosomal degradation7. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.